Scanner Research Synthesis: Congenital Hypofibrinogenemia (Simple Quantitative Form)

This report is based on cached reference abstracts available in references_cache/.

Disease Identity

• Preferred name: Congenital Hypofibrinogenemia (simple quantitative form)
• MONDO: MONDO:0015096 (familial hypofibrinogenemia)
• ISTH classification: Type I (quantitative) congenital fibrinogen disorder
• OMIM: 202400 (afibrinogenemia, autosomal recessive); hypofibrinogenemia is the heterozygous form with partial deficiency
• Note: This entry covers the simple LOF form only. Hepatic Fibrinogen Storage Disease (HFSD/HHHS), caused by specific FGG missense variants driving hepatocyte ER aggregation, is a mechanistically distinct entity treated separately.

Core Pathophysiology

Genetic Mechanism

Congenital hypofibrinogenemia is caused by heterozygous loss-of-function mutations in one of three fibrinogen chain genes: FGA (Aα chain), FGB (Bβ chain), or FGG (γ chain), clustered at chromosome 4q28.

Causative mutation classes (PMID:29316703): 1. Null mutations — complete loss of expression from one allele (large deletions, frameshift, nonsense, splice-site variants) 2. Hypomorphic/secretion-impairing missense mutations — protein produced but mis-folded or retained intracellularly, reducing secretion

Because fibrinogen is a heterohexamer (2×Aα + 2×Bβ + 2×γ), loss of one chain prevents normal hexamer assembly from that allele. Heterozygosity reduces hepatic output by approximately 50%, resulting in circulating fibrinogen levels between 0.5–1.5 g/L (normal range: 2–4 g/L).

Molecular Pathway

1. Heterozygous LOF allele (FGA/FGB/FGG) →
2. Reduced fibrinogen hexamer assembly and secretion by hepatocytes →
3. Low circulating fibrinogen (hypofibrinogenemia; Fg:C <1.5 g/L) →
4. Limited substrate for thrombin-mediated fibrin polymerization →
5. Impaired fibrin clot formation →
6. Level-dependent bleeding diathesis (typically mild; prothrombotic Fg:C >1.0 g/L is broadly protective)

Key Liver Biology

Fibrinogen is an acute-phase protein synthesized exclusively by hepatocytes (CL:0000182). All three chains are co-expressed, assembled in the ER, and secreted as intact hexamers. In the simple quantitative form, liver morphology is normal (no intracellular aggregation), distinguishing this from HFSD.

Clinical Phenotype

Severity Spectrum

Severity correlates directly with residual fibrinogen level (PMID:29316703): - Fg:C ≥1.0 g/L: Generally asymptomatic; most heterozygous carriers fall here - Fg:C 0.7–1.0 g/L: Mild-to-moderate bleeding risk, typically provoked - Fg:C <0.7 g/L: Increased spontaneous bleeding risk; approaches afibrinogenemia spectrum

Major Phenotypes

Hematologic: - Hypofibrinogenemia (obligate, defining) — HP:0011900 - Abnormal bleeding (variable severity) — HP:0001892 - Persistent bleeding after trauma/surgery — HP:0001934

Reproductive (females): - Menorrhagia — HP:0000132 (level-dependent) - Obstetrical complications including recurrent placental abruption — reflects fibrinogen requirement for placental integrity. Fibrinogen is necessary for cytotrophoblast spreading at 4–6 weeks gestation and fetal-maternal vascular development (PMID:29316703).

Laboratory Findings

• Prolonged PT and aPTT (proportional to fibrinogen level)
• Reduced plasma fibrinogen by both Clauss clotting assay and immunologic antigen assay (both low, distinguishing from dysfibrinogenemia where ratio differs)
• Thromboelastography: reduced clot amplitude and firmness

Genetics

Inheritance: Autosomal dominant (heterozygous LOF). Afibrinogenemia (biallelic null) is autosomal recessive. Hypofibrinogenemia is the heterozygous carrier state of autosomal recessive afibrinogenemia alleles, and also arises de novo.

Treatment

Fibrinogen replacement (on-demand and prophylactic): - Fibrinogen concentrate (e.g., Haemocomplettan/RiaSTAP; NCIT:C81126 Fibrinogen Human) is the therapeutic cornerstone (PMID:36055263) - Targets: Fg:C ≥1.0 g/L (general hemostasis), ≥1.5–2.0 g/L perioperatively, ≥2.0 g/L peripartum - Cryoprecipitate (contains fibrinogen, FVIII, vWF, FXIII) is an alternative where concentrate is unavailable - Antifibrinolytics (tranexamic acid) are useful adjuncts for minor bleeds and dental procedures

Asymptomatic management: - Many patients with Fg:C >1.0 g/L require no prophylactic treatment - Awareness of obstetric risks and perioperative prophylaxis planning are important for female patients

Key References

Scope Note

This entry models the simple quantitative (Type I, LOF, liver-normal) form of hypofibrinogenemia. Two mechanistically distinct entities in the congenital fibrinogen disorder family are treated separately: - Afibrinogenemia: biallelic null (AR); more severe - Hepatic Fibrinogen Storage Disease (HFSD): gain-of-toxic-function FGG missense → hepatocyte ER aggregation → hepatopathy (see sibling entry)

Tracker issue: #2727.